Johnson & Johnson (JNJ) EBT Margin (2009 - 2026)
Johnson & Johnson (JNJ) posted EBT Margin of 26.66% for Q2 2026, up 7.08% sequentially from 24.89% in Q1 2026, and down 68.0% YoY from 83.3% in Q2 2025.
Johnson & Johnson (JNJ) EBT Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported EBT Margin for 18 years, with the latest figure at 26.66% in Q2 2026.
- Quarterly EBT Margin fell 68.0% year-over-year to 26.66% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 25.73% (down 445.0% YoY) and the FY2025 annual result came in at 34.59%, up 1580.0% from the prior year.
- EBT Margin advanced to 26.66% in Q2 2026 per JNJ's latest filing, from 24.89% in the prior quarter.
- Over five years, EBT Margin peaked at 62.26% in Q1 2025 and troughed at 6.16% in Q2 2023.
- A 5-year average of 24.15% and a median of 25.17% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2025 and 2026: EBT Margin surged 4489 bps in 2025, then slumped 3737 bps in 2026.
- Over 5 years, EBT Margin stood at 25.87% in 2022, then retreated by 13 bps to 22.56% in 2023, then declined by 23 bps to 17.26% in 2024, then advanced by 17 bps to 20.22% in 2025, then jumped by 32 bps to 26.66% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 26.66%, 24.89%, and 20.22% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 29.63% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 18.19% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 27.53% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -131.41% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -4.34% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 4.21% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 127.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 26.66% |
| Mar 29, 2026 | 24.89% |
| Dec 28, 2025 | 20.22% |
| Sep 28, 2025 | 31.23% |
| Jun 29, 2025 | 27.34% |
| Mar 30, 2025 | 62.26% |
| Dec 29, 2024 | 17.26% |
| Sep 29, 2024 | 14.85% |
| Jun 30, 2024 | 25.61% |
| Mar 31, 2024 | 17.37% |
| Dec 31, 2023 | 22.56% |
| Oct 1, 2023 | 24.43% |
| Jul 2, 2023 | 29.30% |
| Apr 2, 2023 | -6.16% |
| Jan 1, 2023 | 19.26% |
| Oct 2, 2022 | 25.87% |
| Jul 3, 2022 | 25.45% |
| Apr 3, 2022 | 26.22% |
| Oct 3, 2021 | 16.49% |
| Jul 4, 2021 | 28.58% |